Ready to take on Glaxo, Gilead's combo HIV med Biktarvy wins $6B FDA nod
admin 7th February 2018 Uncategorised 0Gilead Sciences is all set for its next big launch. On Wednesday, a day after the company reported a disappointing hepatitis C sales outlook, the drugmaker got a needed boost with the FDA’s approval for HIV combo drug Biktarvy—a product analysts see climbing far past the blockbuster threshold.
More: Ready to take on Glaxo, Gilead's combo HIV med Biktarvy wins B FDA nod
Source: fierce